Xtl Biopharmaceuticals (XTLB) Research & Development (2011 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Research & Development of $50000.0 for Q4 2024, up 933.33% year-on-year from $4838.7 in Q1 2024, and up 192.59% on a QoQ basis from -$54000.0 in Q3 2024.
Xtl Biopharmaceuticals (XTLB) Research & Development (2011 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Research & Development for 14 consecutive years, with $50000.0 the latest figure, recorded in Q4 2024.
- Quarterly Research & Development rose 933.33% year-over-year to $50000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$16000.0 (up 48.39% YoY) and the FY2025 annual result came in at -$28000.0, down 75.0% from the prior year.
- Research & Development grew to $50000.0 in Q4 2024 per XTLB's latest filing, from -$54000.0 in the prior quarter.
- Over the last five years, Research & Development for XTLB reached as high as $54000.0 in Q4 2022 and fell as low as -$54000.0 in Q3 2024.
- A 5-year average of $1350.0 and a median of $6000.0 in 2021 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development slumped 850.0% — and 2024, when it surged 933.33%.
- Year by year, Research & Development stood at $12000.0 in 2020, then tumbled by 50.0% to $6000.0 in 2021, then surged by 800.0% to $54000.0 in 2022, then slumped by 111.11% to -$6000.0 in 2023, then jumped by 933.33% to $50000.0 in 2024.
- According to Business Quant data, Research & Development over the past three periods registered $50000.0, -$54000.0, and -$18000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 343.97 Mn |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 50,000.00 |
| Sep 30, 2024 | -54,000.00 |
| Jun 30, 2024 | -18,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Dec 31, 2023 | -6,000.00 |
| Sep 30, 2023 | -44,000.00 |
| Jun 30, 2023 | 6,000.00 |
| Mar 31, 2023 | 13,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Sep 30, 2022 | -45,000.00 |
| Jun 30, 2022 | -15,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | 6,000.00 |
| Jun 30, 2021 | 6,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Dec 31, 2020 | 12,000.00 |
| Sep 30, 2020 | 40,000.00 |
| Jun 30, 2020 | -11,000.00 |
| Mar 31, 2020 | 3,000.00 |